CG Oncology Past Earnings Performance

Past criteria checks 0/6

CG Oncology's earnings have been declining at an average annual rate of -40%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 160.2% per year.

Key information

-40.0%

Earnings growth rate

6.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-160.2%
Return on equity-13.6%
Net Margin-11,510.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

Oct 04
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

CG Oncology: Promising Data, But Looks Expensive

Aug 26

CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jul 25
CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 09

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 06

Revenue & Expenses Breakdown

How CG Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:CGON Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-79250
31 Mar 241-72140
31 Dec 230-68100
30 Sep 230-5790
31 Dec 220-4460
31 Dec 2110-1850

Quality Earnings: CGON is currently unprofitable.

Growing Profit Margin: CGON is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CGON's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CGON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CGON has a negative Return on Equity (-13.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies